NON-BUPRENORPHINE OPIOID UTILIZATION AMONG PATIENTS USING BUPRENORPHINE/NALOXONE (SUBOXONE)
Author(s)
Daubresse M1, Saloner B2, Pollack H3, Alexander GC4
1Johns Hopkins School of Public Health, Baltimore, MD, USA, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 3University of Chicago, Chicago, IL, USA, 4Johns Hopkins Bloomberg School of Public Health, Center for Drug Safety and Effectiveness, Baltimore, MD, USA
OBJECTIVES: Buprenorphine/naloxone is commonly used to treat opioid dependence, however, non-buprenorphine prescription opioid utilization among these patients has not been well defined. We sought to characterize patterns of opioid utilization among incident buprenorphine/naloxone (Suboxone) users in eleven states. METHODS: We used IMS Health anonymized, individual-level, all-payer pharmacy claims to identify incident users of buprenorphine/naloxone between January 2010 and August 2013. We focused on patients 18 years of age and defined each patient’s first treatment episode as the length of time from the patient’s incident prescription for buprenorphine/naloxone (index fill) until the first day of a gap where the patient had no buprenorphine/naloxone on-hand for 90 or more days. We calculated measures of non-buprenorphine opioid utilization during the first treatment episode as well as during 12-month periods prior to and following this episode. RESULTS: Of the 22655 individuals meeting inclusion criteria, 49% were female and 50% were between 25 and 46 years of age. The median length of the first treatment episode was 79 days (interquartile range [IQR], 30 to 226 days). More than half (58%) of buprenorphine/naloxone recipients filled prescriptions for other opioids following buprenorphine/naloxone treatment and 30% filled at least one opioid prescription during their treatment episode. The median total of morphine milligram equivalents (MME) 12 months prior to treatment was 250 mg/per month (IQR 38 to 1347) then declined to 221 mg/per month (IQR 39 to 1034) and 175 mg/per month (IQR 25 to 1106) during and following the treatment episode, respectively. The median MME per opioid day supplied prior to, during and following the first treatment episode remained constant at 40 mg per day. CONCLUSIONS: Treatment with buprenorphine/naloxone is associated with reduced non-buprenorphine opioid use. However, a substantial proportion of patients fill prescriptions for non-buprenorphine opioids during and following such treatment.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PMH60
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior
Disease
Mental Health, Systemic Disorders/Conditions